drugset
drugset / Trial / NCT00526175

LAL-BR/2001: Study Treatment to Low Risk ALL

NCT00526175 ↗

Phase 4 Completed 150 enrolled PETHEMA Foundation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease

Timeline

Start
2001-06
Primary completion
2015-05
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 1000 mg/m2 Intravenous
Subject Cytarabine Small molecule 16 mg Intravenous
Subject Cytarabine Small molecule 20 mg Intravenous
Subject Cytarabine Small molecule 30 mg Intravenous
Subject Daunorubicin Small molecule 30 mg/m2 Intravenous
Subject Etoposide Small molecule 150 mg/m2 Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule 50 mg/m2 Oral
Subject Methotrexate Small molecule 5 mg Intravenous
Subject Methotrexate Small molecule 8 mg Intravenous
Subject Methotrexate Small molecule 10 mg Intravenous
Subject Methotrexate Small molecule 12 mg Intravenous
Subject Prednisone Other / unclassified 30 mg/m2 Intravenous
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous
Subject asparaginase Protein / enzyme biologic 10000 iu Intramuscular

Indications

acute lymphoblastic leukemia